Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3383072 | 0.82 | LMNA (0.46) | SMN1; SMN2MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL8657004 | 0.82 | SMN1; SMN2 (0.42) | SMN1; SMN2MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL3993817 | 0.82 | BRD4 (0.61) | MEN1KMT2ALMNACES2CES1 | |
| SCHEMBL2551253 | 0.82 | ESR1 (0.50) | MEN1KMT2ALMNAALDH1A1BRD4 | |
| SCHEMBL7282243 | 0.80 | ALOX5 (0.48) | SMN1; SMN2MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL1511329 | 0.80 | HDAC3 (0.44) | SMN1; SMN2LMNAALDH1A1CES2CES1 | |
| SCHEMBL3993015 | 0.80 | CYP1A2 (0.53) | SMN1; SMN2ALOX5CES2CES1BRD4 | |
| SCHEMBL4052998 | 0.80 | ACACB (0.40) | LMNAALDH1A1BRD4 | |
| SCHEMBL356020 | 0.79 | LMNA (0.47) | MEN1KMT2ALMNAALDH1A1CES2 | |
| SCHEMBL11749506 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624209-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9120756-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-09-01 | — | — | US | disclosed |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | MEDIFRON DBT INC. (KR) | 2015-04-09 | — | — | US | disclosed |
| US-8946204-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20150011592-A9 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| US-20140142143-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20120258946-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| WO-2009070045-A2 | IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THIER PHARMACEUTICAL USE | UNIWERSYTET MEDYCZNY IM. KAROLA MARCINKOWSKIEGO W POZNANIU (PL) | 2009-06-04 | — | — | WO | disclosed |
| EP-1432706-A2 | 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027085-A2 | 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| US-4906343-A | Process for the photochemical production of α-aryl propionic acid | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 1990-03-06 | — | — | US | disclosed |
| EP-0336031-A1 | Process for the photochemical production of alpha-aryl propionic acid | Council of Scientific and Industrial Research (IN) | 1989-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV6 | SMN1; SMN2 3176/4885MEN1 4643/4885KMT2A 2137/4885 |
| US-20120258946-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV6 | SMN1; SMN2 3176/4885MEN1 4643/4885KMT2A 2137/4885 |
| US-20150011592-A9 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV2 | SMN1; SMN2 3477/4885MEN1 4575/4885KMT2A 2350/4885 |
| US-20140142143-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV2 | SMN1; SMN2 3477/4885MEN1 4575/4885KMT2A 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.